Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13222)	12/17/2003 1:41:38 PM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

<font color=red>Globe says Provalis a fly in Dimethaid's ointment 2003-12-17 05:39 MT - In the News The Globe and Mail reports in its Wednesday, Dec. 17, edition that Dimethaid Research slid 19 Canadian cents to close on the Toronto Stock Exchange Tuesday at 99 Canadian cents in heavy trading on news that a subsidiary of the drug developer will pay nearly $2.7-million (U.S.) to British drug distributor Provalis Healthcare after losing an arbitrator's decision in a contract dispute. In June, 2002, Dimethaid ended an agreement that gave Provalis exclusive rights to distribute the osteoarthritis lotion Pennsaid in Britain. Provalis sought arbitration six months later. Dimethaid said in The Globe on Jan. 21, when its stock was trading at $2.47 (Canadian), that Provalis's claim was without merit. The following day, when the stock was trading 15 Canadian cents lower, The Globe reported that Dimethaid director Daniel Sooley had sold 22,700 common shares on Dec. 4, 2002, at prices between $2.75 (Canadian) and $2.82 (Canadian). As well, The Globe said Mr. Sooley had sold in December 74,000 shares he held indirectly, at prices between $2.58 (Canadian) and $3.02 (Canadian).